This robot is smaller than the width of a hair đ€Ż And scientists hope it will be used to hunt down and destroy cancer cells.
Category: biotech/medical
Austin startup Lift Aircraft calls Hexa, its electric vertical takeoff and landing (eVTOL) aircraft the future of personal flight. So far, itâs been compared to a drone and a flying car.
Hexa is essentially a recreational vehicle for the air, able to fly in 15-minute intervals at low altitudes. Lift plans to market them to millennials with disposable income and anyone chasing adrenaline, because a pilotâs license isnât required. The COVID-19 pandemic delayed plans, but Lift still says it will be touring locations across the US where anyone meeting height, weight, and age requirements can pay to fly. As of November 2019, Lift says it had more than 15,000 flights on a waitlist to ride Hexa.
The company is also selling a small number of Hexas to buyers who will then rent them out. They cost $495,000, and only five are still available.
Drone solution provider MissionGO has completed the longest organ delivery by drone in Las Vegas last week with the Nevada Donor Network. The two test flights were carrying a human organ and tissue to various locations around Las Vegas.
The first of the two flights was transporting research corneas from the Southern Hills Hospital and Medical Center to Dignity Health at the St. Rose Dominican, San MartĂn Campus. The flight demonstrated the viability, value, efficiency gains, and delivery speed of using drones to deliver organs and medical supplies.
The second flight delivered a research kidney from an airport to a location on the outskirts of a small town in the Las Vegas desert. This second flight was the one that marked the longest organ delivery by drone. The flight beat the previous record that was set in April 2019 also by MissionGO.
Researchers identified some of the most potent and diverse antibodies discovered to date that neutralize SARS-CoV-2, targeting multiple regions on the viral spike.
LEAF president Keith Comito explains the story of Lifespan.io â a crowdsourcing platform and community to support biomedical research aimed at extending healthy human lifespan.
âŒâŒ More info and links below âŒâŒ
HOW CAN YOU SUPPORT US?
ââââââââââââââââââââââââââ
LEAF / Lifespan.io is a 501©(3) nonprofit organization. Everything weâve done thus far and everything we will do in the future is thanks to your support â please stand with us to fight the diseases of aging and increase healthy human lifespan.
âș Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/hero
âș Make a one-time donation and learn about other ways to support us here: http://lifespan.io/support
âș Learn more, and help us #CrowdsourceTheCure: https://www.lifespan.io
âș Subscribe: http://www.youtube.com/user/LifespanIO?sub_confirmation=1
THANKS TO THE SUPPORT OF PEOPLE LIKE YOU, WE HAVE:
ââââââââââââââââââââââââââ
âș Crowdfunded over $400,000 for credible research projects addressing the root causes of aging
âș Worked with amazing channels like @Kurzgesagt â In a Nutshell and @Life Noggin on videos to inform and engage the public in our work.
âș Built up the most trafficked news outlet and online community on the subject of aging research, with over 150,000 members across various platforms and social media: https://www.lifespan.io/news
âș Created a monthly livestreamed Journal Club to explain the latest research to you in real time: https://www.lifespan.io/journalclub
âș Began to host our flagship Ending Age-Related Diseases annual conference in New York City, bringing together researchers, investors, regulators, press, and the public: https://www.lifespan.io/conference
âș Created the premier network of investors focused on supporting this work, the Longevity Investor Network, which holds monthly pitch meetings to review the most promising and credible up-and-coming companies in the field: https://www.lifespan.io/investor
âș Built powerful online tools, such as our Rejuvenation Roadmap, which shows you at glance the latest updates in the field: https://www.lifespan.io/roadmap
âș Began to create educational video content, such as our LifeXtenShow: https://www.lifespan.io/x10
NEWS & SOCIAL MEDIA
ââââââââââââââââââââââââââ
News: https://www.lifespan.io/news
Facebook: https://www.lifespan.io/facebook
Instagram: https://www.lifespan.io/instagram
LinkedIn: https://www.lifespan.io/linkedin
Twitter: https://www.lifespan.io/twitter
Discord: https://www.lifespan.io/discord
Newsletter: https://www.lifespan.io/newsletter
YOUTUBE COLLABORATIONS:
ââââââââââââââââââââââââââ
Kurzgesagt: https://www.youtube.com/watch?v=MjdpR-TY6QU
Life Noggin: https://www.youtube.com/watch?v=EEO4bHbxRgo
Psilocybin startup Compass Pathways goes public at more than $1B. Hereâs why Wall Street is starting to see the value in psychedelics.
For several years, investors and psychonauts have predicted that psychedelic medicine would become the next billion-dollar industry, with some value estimates as high as $100 billion. They said substances like MDMA or psilocybin mushrooms would follow a similar regulatory path that cannabis took to the mainstream, going from a Schedule 1 narcotic to a legal, regulated, and highly lucrative medicine.
At least some of these predictions have rung true. On September 18th, Compass Pathways Plc., a London-based company developing psilocybin into a prescription drug in assisted psychotherapy, went public, listing on Nasdaq. The companyâs stock jumped 71 percent on its first day of trading and is now estimated to be worth $1.3 billion. Compass Pathways declined to comment for this article. Numinus Wellness Inc and Champignon Brands Inc are two other psychedelic companies that have gone public this year.
This month, another psychedelic research company, Mind Medicine Inc. (âMindmedâ), announced their intent to appear on Nasdaq, as well, and some analysts predict it will soon be the next billion-dollar psychedelic company. Havn Life Sciences, which has earned permission from the Canadian government to work with psilocybin, also squeezed onto the Canadian Stock Exchange in September.
Stem cells are a promising experimental treatment for a variety of diseases. Now researchers at the University of Wisconsin-Madison have found that transplanting neurons grown from stem cells into the brains of mice with Parkinsonâs disease repaired the damaged brain circuits, improving the animalsâ motor skills.
In people afflicted with Parkinsonâs, neurons that produce dopamine begin to break down and die. The disease gradually presents as tremors, involuntary movements, and trouble with walking, speaking and other actions. While it currently canât be cured, studies are suggesting new ways to slow progression and reduce severity of symptoms through new drugs or repurposed old ones, deep brain stimulation or probiotic treatments.
But an emerging and potentially ground-breaking treatment involves stem cells. In several studies, researchers have used stem cells to grow new dopamine-producing neurons, and then transplant them into animals. And now the UW-Madison teamâs work has shown that doing so can help restore brain circuits damaged by Parkinsonâs.
This video explains the structural forms of DNA, why DNA have different forms and what are the differences present between each form.
Thank You For Watching.
Please Like And Subscribe to Our Channel: https://www.youtube.com/EasyPeasyLearning
Like Our Facebook Page: https://www.facebook.com/learningeasypeasy/
Join Our Facebook Group: https://www.facebook.com/groups/460057834950033
In a study of gorilla skeletons collected in the wild, Johns Hopkins Medicine researchers and their international collaborators report that aging female gorillas do not experience the accelerated bone loss associated with the bone-weakening condition called osteoporosis, as their human counterparts often do. The findings, they say, could offer clues as to how humans evolved with age-related diseases.
The study was published on Sept. 21, 2020, in Philosophical Translations of the Royal Society B.
âOsteoporosis in humans is a really interesting mechanical problem,â says Christopher Ruff, Ph.D., professor at the Center for Functional Anatomy and Evolution at the Johns Hopkins University School of Medicine. âIn terms of natural selection, there is no evolutionary advantage in developing bone loss with aging to the point of a potential fracture. By looking at close relatives of humans on the evolutionary tree, we can infer more about the origins of this condition.â
Some people are at higher risk of developing obesity because they possess genetic variants that affect how the brain processes sensory information and regulates feeding and behavior. The findings from scientists at the University of Copenhagen support a growing body of evidence that obesity is a disease whose roots are in the brain.
Over the past decade, scientists have identified hundreds of different genetic variants that increase a personâs risk of developing obesity. But a lot of work remains to understand how these variants translate into obesity. Now scientists at the University of Copenhagen have identified populations of cells in the body that play a role in the development of the diseaseâand they are all in the brain.
âOur results provide evidence that biological processes outside the traditional organs investigated in obesity research, such as fat cells, play a key role in human obesity,â says Associate Professor Tune H Pers from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR), at the University of Copenhagen, who published his teamâs findings in the internationally-recognized journal eLife.